Allergan planning sNDA for cariprazine in bipolar I depression after Phase III readout

Allergan plc (NYSE:AGN) and Gedeon Richter plc (Budapest:RICHTER) said cariprazine (MP-214, RGH-188) met the primary endpoint in the Phase III RGH-MD-54 trial to treat

Read the full 245 word article

User Sign In